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T rophoblast invasion is an important and complex process in human pregnancy.  During early preg-
nancy,  the uterine spiral artery is remodeled from a 
small striated vessel to a large flaccid conduit that is 
unresponsive to vasoconstrictors [1].  Extravillous tro-
phoblasts (EVTs) invade the uterus and spiral arteries 
before the fetal-maternal circulation is established to 
ensure sufficient nutrient and oxygen transfer to the 
fetus.  Inadequate trophoblast invasion underlies many 
harmful obstetric diseases.  For example,  poor tropho-
blast infiltration is associated with miscarriage,  pre-
eclampsia,  and intrauterine fetal growth restriction 
[2 , 3].
The endocrine-gland-derived vascular endothelial 
growth factor (EG-VEGF),  also named prokineticin 1 
(PROK1),  is mainly expressed in the steroidogenic 
glands,  ovary,  uterus,  and placenta.  The biological 
activity of EG-VEGF is mediated by two G-protein-
coupled receptors: prokineticin receptor (PROKR) 1 
and PROKR2 [4-6].  In humans,  EG-VEGF is upregu-
lated in the endometrium during pregnancy.  It peaks at 
8-10 weeks of gestation and gradually declines by the 
end of the first trimester.  Placental PROKR1 shows the 
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Extravillous trophoblast (EVT) invasion is important for embryo implantation,  placental development,  and 
successful remodeling of the uterine spiral artery.  Endocrine gland derived-vascular endothelial growth factor 
(EG-VEGF) and matrix metalloproteinases (MMPs) are implicated in EVT invasion; however,  the high con-
centrations found in pregnancy pathologies have not been investigated in non-tumor trophoblasts.  The roles of 
EG-VEGF,  prokineticin receptors (PROKR1/2),  MMP-2,  and MMP-9 in EVT invasion during spiral artery 
remodeling were evaluated using human EVT from HTR-8/SVneo cell lines.  The expression of MMP-2,  MMP-
9,  and mitogen-activated protein kinase (MAPK),  and Akt pathways in HTR-8/SVneo cells treated with recom-
binant EG-VEGF alongside anti-PROKR1 and/or anti-PROKR2 antibodies was evaluated using quantitative 
reverse transcription-PCR and western blotting.  Wound-healing and cell invasion assays were performed to 
assess the migration and invasion of these treated cells.  Interestingly,  20 nM EG-VEGF activated ERK1/2 sig-
naling and upregulated MMP-2 and MMP-9.  This effect was suppressed by anti-PROKR2 antibody via ERK1/2 
downregulation.  Anti-PROKR2 antibody inhibited the migration and invasion of EG-VEGF-stimulated 
HTR-8/SVneo cells.  Elevated concentrations of EG-VEGF enhance EVT invasion in a human trophoblast cell 
line by upregulating MMP-2 and MMP-9 via PROKR2.  These new insights into the regulation of epithelial cell 
invasion may help in developing therapeutic interventions for placental-related diseases during pregnancy.
Key words:  endocrine gland-derived vascular endothelial growth factor,  prokineticin,  extravillous trophoblast,  
matrix metalloproteinase,  obstetric diseases
Received January 12, 2021 ; accepted May 17, 2021.
＊Corresponding author. Phone : +81-86-235-7320; Fax : +81-86-225-9570
E-mail : masuyama@cc.okayama-u.ac.jp (H. Masuyama)
Conflict of Interest Disclosures: No potential conflict of interest relevant 
to this article was reported.
same expression pattern as EG-VEGF,  with its expres-
sion peaking between the 8th and 10th weeks of gesta-
tion,  whereas PROKR2 shows stable expression 
throughout the first trimester of pregnancy [6].  
EG-VEGF expression in tissues in early pregnancy is 
mainly localized to the syncytiotrophoblast (ST) and 
cytotrophoblast (CT) layers [7 , 8].  PROKR1 is mainly 
expressed in the CT and ST,  and PROKR2 is mainly 
expressed in the EVT [9].  EG-VEGF has been shown to 
regulate placental growth,  and it acts as an important 
endocrine factor in placental development [10].  
EG-VEGF has also been shown to be strongly associ-
ated with recurrent miscarriage,  gestational tropho-
blastic disease [11],  and placental pathologies associ-
ated with fetal growth restriction [12] and/or 
preeclampsia [13].
EG-VEGF is an upstream inducer of several matrix 
metalloproteinases (MMPs) and is suggested to be the 
master regulator of MMP production.  MMPs play 
major roles in trophoblast invasion into the uterine wall.  
Trophoblast invasion is influenced by cytokines,  growth 
factors,  and MMPs [14-16].  EG-VEGF has been shown 
to regulate the expression of MMP-2 and MMP-9 [17-
19].  MMP-2 and MMP-9 play critical roles in the regu-
lation of trophoblast invasion.  MMP-2 and MMP-9 are 
considered to be important enzymes that dissociate the 
basement membrane,  extracellular matrix,  and vascu-
lar smooth muscle cell layer and mediate EVT invasion 
[20 , 21].  MMP-2 expression and MMP-9 expression are 
at their highest levels in the placental bed during early 
pregnancy,  mainly localizing to EVT cells at 6-8 weeks 
of gestation,  and they appear to regulate the trophoblast 
infiltration [15].  Downregulation of MMP-2 and/or 
MMP-9 reduces the trophoblast invasion and causes 
abnormal uteroplacental artery remodeling,  which has 
been shown to be associated with preeclampsia [14 ,  
15 , 22].
However,  no previous studies have revealed an 
association between EG-VEGF and MMPs via 
PROKR1/2 during EVT invasion.
Therefore,  the aim of this study was to determine 
the relation between MMPs and cell invasion by 
EG-VEGF through PROKR1 and PROKR2 in HTR-8/
SVneo,  a human EVT cell line.
Materials and Methods
Preparation of cell culture and antibodies. The 
human EVT cell line HTR-8/SVneo (ATCC® CRL-
3271TM) was cultured at 37°C with 5% CO2 using 
RPMI-1640 medium (ATCC® 30-2001TM) containing 
10% fetal bovine serum (FBS) and 1% penicillin/strep-
tomycin.  Anti-human prokineticin R1/PROKR1 and 
prokineticin R2/PROKR2 antibodies (Novus Biochem-
icals,  Littleton,  CO,  USA) were used at 5 µg/mL to 
inhibit the PROKR-mediated signal transduction.
Quantitative reverse transcription-polymerase 
chain reaction and western blotting. HTR-8/SVneo 
cells were incubated for 24 h and treated with or with-
out human recombinant EG-VEGF (20 nM; Pepro-
Tech),  anti-PROKR1 antibody (5 µg/mL),  or anti-
PROKR2 antibody (5 µg/mL).  Total RNA was extracted 
from the cells using an RNeasy Mini Kit (Qiagen,  
Valencia,  CA,  USA) according to the manufacturer’s 
instructions.  The cDNA was reverse-transcribed from 
the total RNA using a High-Capacity cDNA Reverse 
Transcription Kit (Applied Biosystems,  Foster City,  CA,  
USA) according to the manufacturer’s instructions.  
MMP-2 (Hs01548727_m1),  MMP-9 (Hs00957562_m1),  
and β-actin (Hs01060665_g1) mRNAs were assessed.  
β-Actin was used as an internal control.  Polymerase 
chain reaction (PCR) was performed using the STEP 
ONE PCR system (Applied Biosystems) with initial 
denaturation at 95°C for 15 s,  followed by 50 cycles of 
annealing at 60°C,  and a final extension at 60°C for 
1 min.  The experiments were repeated at least three 
times.  The results were expressed using the 2−ΔΔCt 
method.  Real-time PCR results were obtained using the 
comparative CT method.
The levels of MMPs,  mitogen-activated protein 
kinases (MAPKs; including extracellular signal-regu-
lated kinase (ERK) 1/2,  c-jun N-terminal kinase (JNK),  
and p38),  and Akt proteins were assessed using western 
blotting analysis.  Cells were extracted using a lysis buf-
fer (RIPA Lysis and Extraction Buffer; Thermo Fisher 
Scientific).  Each protein was resolved by sodium dodecyl 
sulfate-polyacrylamide gel electrophoresis and electro- 
transferred onto polyvinylidene fluoride (PVDF) mem-
branes (Invitrolon PVDF,  0.45 µm; Invitrogen).  After 
being blocked in 5% skim milk in Tris-buffered saline 
containing 0.1% Tween ‒ 20 for 1 h,  the membranes 
were incubated overnight at 4°C with the following pri-
mary antibodies: anti-MMP-2 (1 : 1000) and anti-
MMP-9 (1 : 1000) (Proteintech); anti-phospho (p)- 
ERK1/2 (1 : 2000),  anti-ERK1/2 (1 : 1000),  anti-p-Akt 
(1 : 2000),  anti-Akt (1 : 1000),  anti-p-p38 (1 : 1000),  
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anti-p38 (1 : 1000),  anti-p-JNK (1 : 1000),  and anti-
JNK (1 : 1000) (Cell Signaling Technology); and anti-
GAPDH (1 : 5000,  Invitrogen).  Each membrane was 
washed and then incubated with HRP-conjugated sec-
ondary antibodies (Cell Signaling Technology) for 1 h at 
24°C.  Signals were then detected using the Amersham 
ECL Prime Western Blotting Detection Reagent (GE 
Healthcare).  The experiments were repeated at least 
three times.  Each band was quantitatively analyzed by 
densitometry using a GT-9500 Image Scanner (Epson,  
Suwa,  Japan) and BioImage BQ 2.0 software (Ann 
Arbor,  MI,  USA).
The wound-healing assay (cell migration assay) and 
cell invasion assays. Cell migration was assessed 
using the CytoSelectTM 24-well Wound-healing Assay 
(Cell Biolabs,  San Diego,  CA,  USA) according to the 
manufacturer’s instructions.  Cells were seeded into the 
inserts of a CytoSelect 24-well plate and cultured over-
night.  The inserts were carefully removed,  leaving a 
precise wound field of 0.9 mm in diameter.  The medium 
was aspirated,  and cells treated with or without human 
recombinant EG-VEGF (20 nM; PeproTech),  anti-
PROKR1 antibody (5 µg/mL),  or anti-PROKR2 anti-
body (5 µg/mL) were incubated for 24 h in the RPMI 
medium supplemented with 10% FBS.  Wound closure 
progress was monitored using a light microscope.  Cell 
invasion was assessed using a CytoSelectTM 24-well cell 
invasion assay kit (8-µm pore size; Cell Biolabs) 
according to the manufacturer’s instructions.  Cells were 
seeded into the upper chamber in the serum-free 
medium treated with or without human recombinant 
EG-VEGF (20 nM; PeproTech),  anti-PROKR1 anti-
body (5 µg/mL),  or anti-PROKR2 antibody (5 µg/mL).  
Media containing 10% FBS were added to the lower 
wells of the invasion plates,  and the plates were incu-
bated for 24 h.  Finally,  migrated cells were counted 
using a light microscope.
Statistical analysis. All data are expressed as the 
mean ± standard error of mean.  The data analysis was 
performed using the Software Package for the Social 
Sciences (SPSS; Armonk,  NY,  USA).  The Mann–
Whitney U-test was used to compare variables,  and a 
p-value of < 0.05 was considered statistically significant.
Results
Activation of ERK1/2 in the HTR-8/SVneo EVT cell 
line by EG-VEGF via PROKR2. First,  we deter-
mined the protein levels of MAPKs (ERKI/2,  JNK,  and 
p38) and Akt proteins in the HTR-8/SVneo EVT cells.  
Western blot analysis showed that JNK,  p38,  and Akt 
proteins were not detected while ERKI/2 was present in 
the EVT cells (Fig. 1A).  The level of phosphorylated 
ERKI/2 (p-ERK) appeared to be slightly increased when 
the cells were treated with recombinant EG-VEGF pro-
tein.  As described previously,  there are 2 receptors for 
EG-VEGF,  PROKRI and PROKR2 [4-6].  To determine 
which receptor was used by EG-VEGF in the EVT cells,  
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Fig. 1　 (A) HTR-8/SVneo cells were incubated for 24 h and then treated with or without human recombinant endocrine-gland-derived 
vascular endothelial growth factor (EG-VEGF) (20 nM).  The expression of phosphor (p)-ERK1/2 and ERK1/2 was analyzed via western 
blotting.  GAPDH was used as an internal control.  Each bar represents the mean ± SEM obtained from three independent experiments.  
(B-C) HTR-8/SVneo cells were incubated for 24 h and then treated with EG-VEGF (20 nM) with either an anti-prokineticin receptor 
(PROKR)1 antibody (5 µg/mL),  an anti-PROKR2 antibody (5 µg/mL),  or both.  The expressions of ERK1/2 and p-ERK1/2 were analyzed 
via western blotting.  GAPDH was used as an internal control.  Each bar represents the mean ± SEM obtained from three independent 
experiments.  ＊P<0.05 compared with the corresponding control as determined by the Mann‒Whitney U-test.
we examined the alteration of ERKI/2 levels in the 
EG-VEGF-treated cells using blocking antibodies 
against PROKRI or PROKR2.  We found that in the 
presence of anti-PROKR2,  the level of activated ERKI/2 
was decreased (Fig. 1B, C).  In contrast,  no decrease in 
p-ERKI/2 levels was observed in the presence of anti-
PROKR1.
Upregulation of MMP-2 and MMP-9 expression in 
the HTR-8/SVneo EVT cell line by EG-VEGF via 
PROKR2. We next examined the MMP-2 and 
MMP-9 mRNA levels in the EVT cells treated with 
recombinant EG-VEGF using quantitative reverse tran-
scription-PCR (RT-qPCR).  The RT-qPCR results 
showed that the relative expression levels of MMP-2 and 
MMP-9 were significantly upregulated after EG-VEGF 
treatment (Fig. 2A).  The expression levels of MMP-2 
and MMP-9 mRNA were significantly suppressed when 
the cells were co-treated with the anti-PROKR2 anti-
body (Fig. 2B).  Furthermore,  western blot analysis 
showed that the expression of MMP-2 and MMP-9 pro-
teins was significantly suppressed when the cells were 
co-treated with the anti-PROKR2 antibody (Fig. 2C).
Migration and invasion of the HTR-8/SVneo cell 
line were enhanced by EG-VEGF signaling. To 
determine whether the migration of HTR-8/SVneo cells 
was enhanced by EG-VEGF signaling,  we performed a 
wound-healing assay (Fig. 3A) and calculated the per-
centages of cells capable of migration (Fig. 3B).  
Compared with recombinant EG-VEGF alone (50.6%),  
the percentages of cells capable of migration signifi-
cantly decreased to 32. 0% and 35.0% in the assays in 
which anti-PROKR2 antibody and both anti-PROKR1 
and anti-PROKR2 antibodies,  respectively,  were used 
(Fig. 3B).
The invasion of HTR-8/SVneo cells was further 
examined by a cell invasion assay (Fig. 3C).  The per-
centages of cells capable of invasion decreased to 
92.4%,  51.4%,  and 56.0% in the presence of the anti-
PROKR1,  anti-PROKR2,  and both antibodies,  respec-
tively.  The percentages of the cells capable of invasion 
showed especially large and significant decreases in the 
presence of the anti-PROKR2 antibody and both anti-
bodies (Fig. 3D).
These results suggest that EG-VEGF upregulated the 
expression of MMP-2 and MMP-9 and facilitated the 
invasion and migration of EVT via PROKR2 (Fig. 4).
Discussion
In this study,  we used immortalized extravillous CTs 
isolated from human placenta (HTR-8/SVneo) and 
anti-PROKR antibodies to elucidate the role of the 
EG-VEGF signaling pathway in EVT invasion.  EG- 
VEGF induced upregulation of ERK1/2 and MMP-2.  
MMP-9,  EVT migration,  and invasion were inhibited 
by the anti-PROKR2 antibody.  The anti-PROKR1 anti-
body did not inhibit the expression of MMPs or cell 
invasion,  suggesting that PROKR1 signaling is not 
dominant in EVT.  These results suggest that an elevated 
EG-VEGF level induces the expression and activation of 
MMP-2 and MMP-9 and promotes EVT infiltration via 
PROKR2 signaling.
The role of EG-VEGF in human pregnancy is 
strongly associated with trophoblast invasion and 
migration.  EG-VEGF signaling is mediated by two 
G-protein-coupled receptors,  PROKR1 and PROKR2,  
and results in the phosphorylation of MAPK and Akt 
serine/threonine kinase.  PROKR1 is abundantly 
expressed in CTs,  placental microvascular endothelial 
cells (HPECs),  and Hofbauer cells (Ho),  whereas 
PROKR2 is mainly expressed in STs,  HPECs,  Ho,  and 
EVT.  EG-VEGF regulates trophoblast infiltration in 
human gestational tissues.  The mechanism by which 
this regulation occurs is thought to involve the activa-
tion of oxygen tension,  human chorionic gonadotro-
pin,  inflammatory cytokines,  and metalloproteinases 
[13].
Wang et al.  showed that EG-VEGF activates ERK1/2 
signaling,  and then upregulates MMP-2 and MMP-9 in 
human EVT HTR-8/SVneo cells [18].  Zhang et al.  
showed that elevated miR-141 and miR-200a levels 
inhibit the expression of EG-VEGF and the down-
stream ERK1/2,  MMP-2,  and MMP 9 signaling,  as well 
as cilia formation,  thereby leading to defective tropho-
blast invasion [19].  Traboulsi et al.  showed that chorio-
carcinoma development and metastasis were signifi-
cantly suppressed in pregnant mice after treatment with 
PROKR1 or PROKR2 antagonists.  They also found that 
PROKR2 antagonists had a stronger inhibitory effect 
than did PROKR1 antagonists [11].  However,  Hoffmann 
et al.  demonstrated that EG-VEGF inhibits trophoblast 
migration and invasion,  both in HTR and explant 
models [9].  Because in this study they used a concen-
tration of EG-VEGF that mimics the physiological lev-
els found during the first trimester,  one can speculate 
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Fig. 2　 (A) HTR-8/SVneo cells were incubated for 24 h and then treated with or without human recombinant endocrine-gland-derived 
vascular endothelial growth factor (EG-VEGF) (20 nM).  The expressions of matrix metalloproteinase (MMP)-2 and MMP-9 were analyzed 
via RT-qPCR.  Data are presented as the mean ± SEM.  (B) HTR-8/SVneo cells were incubated for 24 h and then treated with EG-VEGF 
(20 nM) with either an anti-prokineticin receptor antibody (PROKR)1 (5 µg/mL),  an anti-PROKR2 antibody (5 µg/mL),  or both.  The expres-
sions of MMP-2 and MMP-9 were analyzed via RT-qPCR.  Data are presented as the mean ± SEM.  (C) HTR-8/SVneo cells were incu-
bated for 24 h and then treated with EG-VEGF (20 nM) with either an anti-PROKR1 antibody (5 µg/mL),  an anti-PROKR2 antibody (5 µg/
mL),  or both.  The expressions of MMP-2 and MMP-9 were analyzed via western blotting.  GAPDH was used as an internal control.
The data are presented as the mean ± SEM.  ＊P<0.05 compared with the corresponding control as determined by the Mann‒Whitney 
U-test.





Fig. 3　 (A-B) The migration of HTR-8/SVneo cells was assessed using a CytoSelectTM 24-well wound-healing assay kit.  HTR-8/SVneo 
cells were treated with endocrine-gland-derived vascular endothelial growth factor (EG-VEGF) (20 nM) with either an anti-prokineticin recep-
tor antibody (PROKR)1 (5 µg/mL),  an anti-PROKR2 antibody (5 µg/mL),  or both.
(C-D) The invasion of HTR-8/SVneo cells was assessed using a CytoSelectTM 24-well cell invasion assay kit.  HTR-8/SVneo cells were 
treated with EG-VEGF (20 nM) with either an anti-PROKR1 antibody (5 µg/mL),  an anti-PROKR2 antibody (5 µg/mL),  or both.  Data are 
presented as the mean ± SEM.  ＊P<0.05 compared with the corresponding control as determined by the Mann‒Whitney U-test.
that EG-VEGF inhibits trophoblast invasion at low 
concentrations and exerts an opposite effect under 
pathological conditions when its concentrations are 
elevated,  such as choriocarcinoma and growth restric-
tion [11 , 12].  The association between PROKR1/2 and 
MMPs during EVT invasion remains largely unex-
plored.  Interestingly,  we found that the expressions of 
ERK1/2,  MMP-2,  and MMP-9 were attenuated after 
anti-PROKR2 antibody treatment,  indicating that sup-
pressing the PROKR2 pathway inhibited the functions 
of EVT,  possibly in HTR-8/SVneo cells.
One limitation of the present study is our heavy reli-
ance on the HTR-8/SVneo cell line in the experiments.  
Although HTR-8/SVneo cells are derived from healthy 
human placentas,  it would be ideal to use primary cells 
to mimic in vivo placental invasion.
In conclusion,  our results demonstrated that EG- 
VEGF upregulates MMP-2 and MMP-9 via ERK1/2 and 
PROKR2 to induce EVT invasion.  Thus,  abnormal 
PROKR2 expression may impair EVT invasion during 
pregnancy and cause placental-related diseases.
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